Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OMER
OMER logo

OMER Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Omeros Corp (OMER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
11.040
1 Day change
-0.99%
52 Week Range
17.650
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

OMER is not a strong buy right now for a beginner long-term investor with $50,000-$100,000. The setup is mixed: pre-market price is weak, technicals are still below key trend levels, and there is no recent news or financial update to support a fresh long-term entry. Options sentiment is mildly bullish, and hedge funds are buying, but without a strong catalyst or clear bullish trend, the better call is to hold and wait for confirmation.

Technical Analysis

OMER is trading pre-market at 11.13, slightly down 0.18%. The trend is not yet bullish: MACD histogram is -0.354 and still below zero, while moving averages are converging, which suggests indecision rather than a confirmed uptrend. RSI_6 at 26.034 is very weak/oversold-like, but it is not enough by itself to confirm reversal. Price is below the pivot at 12.386 and near support at 10.793, so the stock is still trading in a vulnerable zone rather than a confirmed breakout area.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is mildly bullish because both put-call ratios are below 1.0, suggesting more call activity than put activity. Open interest is 46,527 calls vs 26,257 puts, and volume is 591 calls vs 304 puts. Implied volatility is high at 95.76, meaning options traders expect a sizable move, but that does not by itself confirm direction. Overall, options lean slightly bullish.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
6

Positive Catalysts

  • ["Hedge funds are buying aggressively, with buying amount up 185,085.19% over the last quarter.", "Options flow is mildly bullish with put-call ratios below 1.0.", "Stock pattern data suggests modest upside probabilities over 1 day, 1 week, and 1 month.", "RSI is very weak, which can sometimes precede a rebound if buyers step in."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh event-driven catalyst.", "MACD remains below zero, showing the trend is still weak.", "Price is below the pivot level and not yet reclaiming resistance.", "No recent insider buying support; insiders are neutral.", "No recent congress trading data available.", "Financial snapshot data is unavailable, limiting confidence in the fundamental picture."]

Financial Performance

Latest quarter financials were not available due to a data error, so I cannot confirm revenue or earnings trends. Because the latest quarter season is missing, there is no reliable financial growth update to support a long-term buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided, so the Wall Street pros and cons view cannot be fully assessed. Based on the available information, the pros are hedge fund accumulation and mildly bullish options sentiment; the cons are weak technicals, no recent news catalyst, and no visible financial confirmation.

Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
Wall Street analysts forecast OMER stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 11.150
sliders
Low
36
Averages
43.67
High
55
Current: 11.150
sliders
Low
36
Averages
43.67
High
55
H.C. Wainwright
Brandon Folkes
maintain
$20 -> $40
AI Analysis
2026-01-08
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20 -> $40
AI Analysis
2026-01-08
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Omeros to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a "critical inflection point" for Omeros.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$20
2025-12-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20
2025-12-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. H.C. Wainwright's current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OMER
Unlock Now

People Also Watch